APVO logo

Aptevo Therapeutics (APVO) Company Overview

Profile

Full Name:

Aptevo Therapeutics Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

July 20, 2016

Indexes:

Not included

Description:

Aptevo Therapeutics (APVO) is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases. They create unique treatments using their proprietary technology, aiming to improve patient outcomes and provide new options for healthcare providers.

Events Calendar

Earnings

Next earnings date:

Mar 5, 2025

Recent quarterly earnings:

Nov 7, 2024

Recent annual earnings:

Mar 5, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Dec 4, 2024

Analyst ratings

Recent major analysts updates

May 13, 22 Piper Sandler
Overweight
May 28, 21 Roth Capital
Buy
Nov 25, 20 Roth Capital
Buy
Nov 25, 20 PiperJaffray
Overweight
Nov 11, 20 Piper Sandler
Overweight
Apr 11, 18 Roth Capital
Buy
Sep 9, 16 Piper Sandler
Overweight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025
Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025
Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025
APVO
accesswire.comJanuary 15, 2025

Also giving an in-session talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR® Platform," showcasing Aptevo's drug engineering and rational drug design expertise SEATTLE, WA / ACCESSWIRE / January 15, 2025 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced that Peter Pavlik, PhD, Senior Director of Protein Engineering, will chair a session titled "Bi and Multispecific Biologics" and present a talk,"Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR® Platform," at the Cambridge Healthcare Institute's Pep Talk conference today. Details Session Title: Bi and Multispecific Biologics Talk Title: Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR™ Platform (talk being given as part of this session) Session Chair and Talk Presenter: Peter Pavlik, PhD Date/Time: Wednesday, January 15th from 3:15-5:20 US Pacific time.

Are Medical Stocks Lagging Aptevo Therapeutics (APVO) This Year?
Are Medical Stocks Lagging Aptevo Therapeutics (APVO) This Year?
Are Medical Stocks Lagging Aptevo Therapeutics (APVO) This Year?
APVO
zacks.comJanuary 10, 2025

Here is how Aptevo Therapeutics Inc. (APVO) and Accuray (ARAY) have performed compared to their sector so far this year.

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds
Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds
Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds
APVO
accesswire.comDecember 12, 2024

SEATTLE, WA / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 823,544 shares of common stock of the Company originally issued in August 2023, in November 2023, in April 2024, in July 2024 and September 2024, all at a reduced exercise price of $7.50 per share. The shares of common stock issuable upon exercise of the outstanding warrants are registered pursuant to effective registration statements on Form S-1 (File No.

Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects
Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects
Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects
APVO
accesswire.comDecember 4, 2024

Powered by Aptevo's proprietary ADAPTIR-FLEX®platform, antibody innovation targeting difficult-to-treat cancers SEATTLE, WA / ACCESSWIRE / December 4, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced additional details about the Company's preclinical bispecific antibody, APVO442, differentiated to target prostate cancer with enhanced precision and minimized safety risk. APVO442 is the first molecule developed using Aptevo's cutting-edge ADAPTIR-FLEX platform, which is driving innovation in antibody engineering for complex disease management.

Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm
Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm
Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm
APVO
accesswire.comNovember 22, 2024

Developing innovative bispecific antibodies for monotherapy and combination with the potential to expand the frontiers of cancer treatment SEATTLE, WA / ACCESSWIRE / November 22, 2024 / Aptevo Therapeutics (NASDAQ:APVO), a leader in the development of novel bispecific antibodies for cancer treatment, provided additional details about its robust oncology pipeline which is poised to potentially address some of the most challenging and aggressive forms of cancer in both blood and solid tumors. As bispecific antibodies gain prominence for their revolutionary therapeutic potential and expanding market opportunities, Aptevo's differentiated platforms (ADAPTIR® and ADAPTIR-FLEX®) and promising clinical results across two clinical programs (mipletamig and ALG.APV-527), together with preclinical assets (APVO711, APVO603 and APVO442) are demonstrating how bispecifics rationally differentiated for safety and targeted efficacy may impact the future of cancer care.

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update
Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update
Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update
APVO
accesswire.comNovember 7, 2024

Company Achieves Milestones in Both Clinical Programs Initiates Mipletamig Phase 1b/2 Clinical Trial, "RAINIER," in Frontline Acute Myeloid Leukemia, Informed by Positive Dose Escalation Trial Results Presented Interim Data from ALG.APV-527 Phase 1 Trial in Multiple Solid Tumors at the European Society for Medical Oncology Congress Additional Favorable Data to be Presented at the Society for Immunotherapy of Cancer Conference on November 8th Raises $5.75 Million in the Quarter SEATTLE, WA / ACCESSWIRE / November 7, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the quarter ending September 30, 2024 and provided a business update. Business Highlights Aptevo met multiple clinical milestones in the third quarter, including: Based on positive safety, tolerability efficacy and durability data in its completed dose escalation trial, Aptevo Initiated the mipletamig Phase 1b/2 dose optimization trial, "RAINIER," as part of its ongoing program to evaluate the compound in combination with standard of care venetoclax + azacitidine in frontline patients with acute myeloid leukemia (AML).

Aptevo Therapeutics (APVO) Upgraded to Buy: Here's What You Should Know
Aptevo Therapeutics (APVO) Upgraded to Buy: Here's What You Should Know
Aptevo Therapeutics (APVO) Upgraded to Buy: Here's What You Should Know
APVO
zacks.comAugust 15, 2024

Aptevo Therapeutics (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update
Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update
Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update
APVO
accesswire.comAugust 8, 2024

SEATTLE, WA / ACCESSWIRE / August 8, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the quarter ended March 31, 2024 and provided a business update. "After the successful completion of our APVO436 dose expansion trial, where we saw a 91% clinical benefit rate and an excellent safety, tolerability and duration of remission profile, we worked in the second quarter to finalize plans for the launch of the first part of our Phase 1b/2 trial, a dose optimization study, continuing evaluation of APVO436 in combination with venetoclax and azacitidine for the treatment of Acute Myeloid Leukemia (AML) in frontline patients.

Aptevo Therapeutics Announces Closing of $2.75 Million Offering
Aptevo Therapeutics Announces Closing of $2.75 Million Offering
Aptevo Therapeutics Announces Closing of $2.75 Million Offering
APVO
accesswire.comJuly 1, 2024

SEATTLE, WA / ACCESSWIRE / July 1, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the closing of its previously announced offering of (i) 5,339,806 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 10,679,612 shares of its common stock (the "Common Warrants") at a purchase price of $0.515 per share and associated Common Warrant in a registered direct offering priced at-the-market under Nasdaq rules. Each share of common stock is being offered together with two Common Warrants, each to purchase one share of common stock.

Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why
Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why
Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why
APVO
Zacks Investment ResearchApril 16, 2024

Aptevo's stock drops following the issuance of additional shares at a discounted price, resulting in a significant dilution of existing shareholders.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the ticker symbol for Aptevo Therapeutics?
  • Does Aptevo Therapeutics pay dividends?
  • What sector is Aptevo Therapeutics in?
  • What industry is Aptevo Therapeutics in?
  • What country is Aptevo Therapeutics based in?
  • When did Aptevo Therapeutics go public?
  • Is Aptevo Therapeutics in the S&P 500?
  • Is Aptevo Therapeutics in the NASDAQ 100?
  • Is Aptevo Therapeutics in the Dow Jones?
  • When was Aptevo Therapeutics's last earnings report?
  • When does Aptevo Therapeutics report earnings?
  • Should I buy Aptevo Therapeutics stock now?

What is the ticker symbol for Aptevo Therapeutics?

The ticker symbol for Aptevo Therapeutics is NASDAQ:APVO

Does Aptevo Therapeutics pay dividends?

No, Aptevo Therapeutics does not pay dividends

What sector is Aptevo Therapeutics in?

Aptevo Therapeutics is in the Healthcare sector

What industry is Aptevo Therapeutics in?

Aptevo Therapeutics is in the Biotechnology industry

What country is Aptevo Therapeutics based in?

Aptevo Therapeutics is headquartered in United States

When did Aptevo Therapeutics go public?

Aptevo Therapeutics's initial public offering (IPO) was on July 20, 2016

Is Aptevo Therapeutics in the S&P 500?

No, Aptevo Therapeutics is not included in the S&P 500 index

Is Aptevo Therapeutics in the NASDAQ 100?

No, Aptevo Therapeutics is not included in the NASDAQ 100 index

Is Aptevo Therapeutics in the Dow Jones?

No, Aptevo Therapeutics is not included in the Dow Jones index

When was Aptevo Therapeutics's last earnings report?

Aptevo Therapeutics's most recent earnings report was on Nov 7, 2024

When does Aptevo Therapeutics report earnings?

The next expected earnings date for Aptevo Therapeutics is Mar 5, 2025

Should I buy Aptevo Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions